

# **Dysautonomia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/DF17DBF22007EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: DF17DBF22007EN

## **Abstracts**

The 7 major dysautonomia markets reached a value of US\$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 9.22% during 2024-2034.

The dysautonomia market has been comprehensively analyzed in IMARC's new report titled "Dysautonomia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dysautonomia is a medical condition characterized by impairment or dysfunction of the autonomic nervous system. The autonomic nervous system controls and regulates involuntary bodily functions, such as blood pressure, heart rate, digestion, temperature regulation, bladder and bowel control, etc. Some of the common symptoms associated with the ailment are dizziness, lightheadedness, fainting or near-fainting episodes, rapid or irregular heart rate, excessive or lack of sweating, constipation, fatigue, cognitive impairment, problems with body temperature regulation, etc. Various other indications may include headaches, sleep disturbances, anxiety, difficulty concentrating, muscle weakness, fluctuations in blood pressure, etc. The diagnostic process typically begins with a thorough medical history and physical examination, where the healthcare provider will assess symptoms and look for signs of autonomic dysfunction. Numerous specialized tests, including autonomic function tests, such as tilt table testing, autonomic reflex testing, quantitative sudomotor axon reflex testing, etc., are also conducted. Additional diagnostic procedures, including blood investigations, imaging studies, neurological assessments, cardiac evaluations, etc., may be utilized to rule out other potential causes and evaluate overall autonomic function.

The increasing cases of gene mutations that predispose individuals to autonomic nerve

malfunction or degeneration are primarily driving the dysautonomia market. In addition to this, the rising prevalence of several associated risk factors, such as neurodegenerative disorders, chronic infections, physical trauma or injury to the autonomic nerves or spinal cord, diabetic neuropathy, etc., is acting as another significant growth-inducing factor. Moreover, the inflating demand for neurostimulation techniques, including deep brain stimulation (DBS) and spinal cord stimulation (SCS), which involve the implantation of electrodes that deliver controlled electrical impulses to targeted areas of the nervous system, thereby modulating its activity and alleviating autonomic dysfunction, is further creating a positive outlook for the market. Additionally, numerous key players are making extensive investments in R&D activities to introduce medications that target specific neurotransmitter receptors, modulate ion channels, and enhance autonomic function. This, in turn, is also bolstering the market growth. Furthermore, the emerging popularity of gut microbiome interventions, such as fecal microbiota transplantation, etc., since they aid in restoring gut dysbiosis, reducing inflammation, and improving autonomic function, is expected to drive the dysautonomia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the dysautonomia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dysautonomia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dysautonomia market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the dysautonomia market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the dysautonomia market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current dysautonomia marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance  
Key Questions Answered in this Report:  
Market Insights

How has the dysautonomia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the dysautonomia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the dysautonomia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of dysautonomia across the seven major markets?

What is the number of prevalent cases (2018-2034) of dysautonomia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of dysautonomia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with dysautonomia across the seven major markets?

What is the size of the dysautonomia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of dysautonomia?

What will be the growth rate of patients across the seven major markets?

### Dysautonomia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for dysautonomia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dysautonomia market?

What are the key regulatory events related to the dysautonomia market?

What is the structure of clinical trial landscape by status related to the dysautonomia market?

What is the structure of clinical trial landscape by phase related to the dysautonomia market?

What is the structure of clinical trial landscape by route of administration related to the dysautonomia market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 DYSAUTONOMIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### 5 DYSAUTONOMIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 DYSAUTONOMIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 DYSAUTONOMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 DYSAUTONOMIA - UNMET NEEDS**

## **10 DYSAUTONOMIA - KEY ENDPOINTS OF TREATMENT**

## **11 DYSAUTONOMIA - MARKETED PRODUCTS**

- 11.1 List of Dysautonomia Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 DYSAUTONOMIA - PIPELINE DRUGS**

### 12.1 List of Dysautonomia Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. DYSAUTONOMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. DYSAUTONOMIA – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 DYSAUTONOMIA - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Dysautonomia - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Dysautonomia - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Dysautonomia - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Dysautonomia - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Dysautonomia - Access and Reimbursement Overview

- 15.4 Market Scenario - Germany
  - 15.4.1 Dysautonomia - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Dysautonomia - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Dysautonomia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Dysautonomia - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Dysautonomia - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Dysautonomia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Dysautonomia - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Dysautonomia - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Dysautonomia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Dysautonomia - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Dysautonomia - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Dysautonomia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Dysautonomia - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Dysautonomia - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Dysautonomia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Dysautonomia - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Dysautonomia - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Dysautonomia - Access and Reimbursement Overview

## **16 DYSAUTONOMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 DYSAUTONOMIA MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 DYSAUTONOMIA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Dysautonomia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DF17DBF22007EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DF17DBF22007EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

